AFFY Quote, Financials, Valuation and Earnings

Cantabio Pharmaceuticals, Inc. has a net margin of -- compared to Affymax, Inc.'s net margin of --. Affymax, Inc.'s return on equity of -- beat Cantabio Pharmaceuticals, Inc.'s return on equity of --.

Affymax, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cantabio Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Affymax, Inc. has higher upside potential than Cantabio Pharmaceuticals, Inc., analysts believe Affymax, Inc. is more attractive than Cantabio Pharmaceuticals, Inc..

Affymax, Inc. has a beta of 7.774, which suggesting that the stock is 677.424% more volatile than S&P 500. In comparison Cantabio Pharmaceuticals, Inc. has a beta of -0.149, suggesting its less volatile than the S&P 500 by 114.935%.

Affymax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cantabio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Affymax, Inc. pays -- of its earnings as a dividend. Cantabio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Affymax, Inc. quarterly revenues are --, which are smaller than Cantabio Pharmaceuticals, Inc. quarterly revenues of --. Affymax, Inc.'s net income of -- is lower than Cantabio Pharmaceuticals, Inc.'s net income of --. Notably, Affymax, Inc.'s price-to-earnings ratio is -- while Cantabio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Affymax, Inc. is 0.98x versus -- for Cantabio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Scopus Biopharma, Inc. has a net margin of -- compared to Affymax, Inc.'s net margin of --. Affymax, Inc.'s return on equity of -- beat Scopus Biopharma, Inc.'s return on equity of --.

Affymax, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Scopus Biopharma, Inc. has an analysts' consensus of -- which suggests that it could grow by 2399900%. Given that Scopus Biopharma, Inc. has higher upside potential than Affymax, Inc., analysts believe Scopus Biopharma, Inc. is more attractive than Affymax, Inc..

Affymax, Inc. has a beta of 7.774, which suggesting that the stock is 677.424% more volatile than S&P 500. In comparison Scopus Biopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Affymax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Scopus Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Affymax, Inc. pays -- of its earnings as a dividend. Scopus Biopharma, Inc. pays out -- of its earnings as a dividend.

Affymax, Inc. quarterly revenues are --, which are smaller than Scopus Biopharma, Inc. quarterly revenues of --. Affymax, Inc.'s net income of -- is lower than Scopus Biopharma, Inc.'s net income of --. Notably, Affymax, Inc.'s price-to-earnings ratio is -- while Scopus Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Affymax, Inc. is 0.98x versus -- for Scopus Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Syros Pharmaceuticals, Inc. has a net margin of -- compared to Affymax, Inc.'s net margin of --. Affymax, Inc.'s return on equity of -- beat Syros Pharmaceuticals, Inc.'s return on equity of --.

Affymax, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Syros Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 199900%. Given that Syros Pharmaceuticals, Inc. has higher upside potential than Affymax, Inc., analysts believe Syros Pharmaceuticals, Inc. is more attractive than Affymax, Inc..

Affymax, Inc. has a beta of 7.774, which suggesting that the stock is 677.424% more volatile than S&P 500. In comparison Syros Pharmaceuticals, Inc. has a beta of 1.113, suggesting its more volatile than the S&P 500 by 11.326%.

Affymax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syros Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Affymax, Inc. pays -- of its earnings as a dividend. Syros Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Affymax, Inc. quarterly revenues are --, which are smaller than Syros Pharmaceuticals, Inc. quarterly revenues of --. Affymax, Inc.'s net income of -- is lower than Syros Pharmaceuticals, Inc.'s net income of -$6.4M. Notably, Affymax, Inc.'s price-to-earnings ratio is -- while Syros Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Affymax, Inc. is 0.98x versus 0.05x for Syros Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Trevena, Inc. has a net margin of -- compared to Affymax, Inc.'s net margin of -1745.23%. Affymax, Inc.'s return on equity of -- beat Trevena, Inc.'s return on equity of -17098.81%.

Affymax, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Trevena, Inc. has an analysts' consensus of -- which suggests that it could grow by 41566.67%. Given that Trevena, Inc. has higher upside potential than Affymax, Inc., analysts believe Trevena, Inc. is more attractive than Affymax, Inc..

Affymax, Inc. has a beta of 7.774, which suggesting that the stock is 677.424% more volatile than S&P 500. In comparison Trevena, Inc. has a beta of 0.602, suggesting its less volatile than the S&P 500 by 39.809%.

Affymax, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trevena, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Affymax, Inc. pays -- of its earnings as a dividend. Trevena, Inc. pays out -- of its earnings as a dividend.

Affymax, Inc. quarterly revenues are --, which are smaller than Trevena, Inc. quarterly revenues of $283K. Affymax, Inc.'s net income of -- is lower than Trevena, Inc.'s net income of -$4.9M. Notably, Affymax, Inc.'s price-to-earnings ratio is -- while Trevena, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Affymax, Inc. is 0.98x versus 0.02x for Trevena, Inc.. Usually stocks with elevated PS ratios are considered overvalued.